Contact Us

URALCHEM and the Ziedot.lv Fund Combine to Help Seriously Ill Children in Latvia

URALCHEM and a leading charitable organization of Latvia, the fund of Ziedot.lv, have agreed to work together to help seriously ill children who need specific treatment or rehabilitation using leading Russian clinics.
    MOSCOW, RUSSIA, October 03, 2012 /24-7PressRelease/ -- URALCHEM and a leading charitable organization of Latvia, the fund of Ziedot.lv, have agreed to work together to help seriously ill children who need specific treatment or rehabilitation using leading Russian clinics. URALCHEM will provide funding for the hospitalization and treatment of children to the amount of 80 thousand Euros. A corresponding agreement has been signed today by URALCHEM CEO Dmitry Konyaev and Manager of the Fund Ziedot.lv Ruta Dimanta.

Dmitry Konyaev, CEO of URALCHEM, OJSC:

"Since 2009, URALCHEM has been implementing a large-scale logistics project involving the creation of a terminal for transhipment of mineral fertilizers in the Latvian port of Riga. Traditionally, in all regions where URALCHEM does business, we pursue a socially responsible policy, which aims to address the socio-economic problems of the people of these regions. One of the priorities of our policy has always been to help children. In a joint program with Ziedot.lv we will help families of different nationalities living in Latvia who need financial and medical assistance. "

Ruta Dimanta, Head of the Fund Ziedot.lv:

"The programme will help seriously ill children who need treatment in Russian clinics, and whose families are not able to cover all the costs. URALCHEM's support is particularly important because the treatment of Latvian residents outside the European Union is not funded by the state. In practice, in cases with rare or complex diseases, it is necessary to seek help outside Latvia. Children deserve to have the highest level of treatment based on modern scientific developments. "

The agreement stipulates that, within a specially designed charity programme - "Help for seriously ill children", 20 children from Latvia will be treated in leading medical institutions in Russia during the coming year. The programme participants are selected by the fund Ziedot.lv on the basis of doctor's recommendations and requests from parents for financial assistance. Assistance is needed in the treatment of diseases such as autism, vision recovery, cerebral palsy and developmental delay.

With this initiative by URALCHEM, Latvian children will now be able to access world leading medical treatment not only within the EU but in Russia as well.

URALCHEM, OJSC is one of the largest producers of nitrogen and phosphate fertilisers in Russia and the CIS with production capacities of over 2.5 million tonnes of ammonium nitrate, 2.8 million tonnes of ammonia, 0.8 million tonnes of MAP and DAP, 0.8 million tonnes of complex fertilisers and 1.2 million tonnes of urea. URALCHEM, OJSC is the second largest ammonium nitrate producer in the world and number one in Russia, the second largest producer of nitrogen fertilisers in Russia. Key production assets of URALCHEM, OJSC include Azot Branch of URALCHEM, OJSC in Berezniki, Perm Region; OJSC Minudobrenia, Perm; MFP Kirovo-Chepetsk Chemical Works, OJSC Branch in Kirovo-Chepetsk, Kirov region; Voskresensk Mineral Fertilisers, OJSC in Voskresensk, Moscow region.

Website: http://www.uralchem.com


# # #

Read more Press Releases from Aleksey Ismailov:


Comment on this story...

Share This Story


Email this Story

Contact Information


Aleksey Ismailov
Uralchem

Moscow, Russia
Russische Föderation
Voice: 74957218989
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?


I like it! 0

Disclaimer


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.